Blood Cancer: November 2006 Archives

Delta cancer alarm


leukemia cellsAN unknown genetic and environmental cocktail has sparked a mysterious rise in blood cancers in Australia with rates almost doubling over the past two decades.

While most cancers have declined or stabilised, the incidence of blood cancers such as lymphoma is on the rise.

New cases of blood cancers have spiked from nearly 4000 cases in 1983 to more than 7500 diagnosed in 2001.

Blood cancers include leukemia and Hodgkin's lymphoma, the condition from which singer Delta Goodrem suffered.

Geron presents encouraging data on cancer inhibitor


GRN163L moleculeGeron has presented encouraging clinical trial data for its telomerase inhibitor cancer drug, GRN163L.

The data demonstrated the safety, tolerability and predicted pharmacokinetics in low-dose cohorts from a phase I/II trial in patients with chronic lymphocytic leukemia and a phase I trial in patients with solid tumors.

"This is the first time telomerase inhibition has been tested in cancer patients. The excellent tolerability and pharmacokinetics observed so far enable us to advance to the therapeutic dose cohorts, where we hope to demonstrate safe, sustained telomerase inhibition in the targeted tumor cells," said Alan Colowick, Geron's president, oncology.

About this Archive

This page is a archive of entries in the Blood Cancer category from November 2006.

Blood Cancer: October 2006 is the previous archive.

Blood Cancer: December 2006 is the next archive.

Find recent content on the main index or look in the archives to find all content.